Drug Target Review2024-05-15T12:00:21
The experimental therapy eliminated 90 percent of HSV-1 after facial infection and 97 percent of HSV-1 after genital infection.
Already a member? Sign in
By highlighting cutting-edge research and its practical applications, Drug Target Review enables readers to make decisions that accelerate innovation, translate discoveries into therapies, and create tangible benefits for patients worldwide.
By becoming a member you join a connected and collaborative community driving the industry forward. Member benefits include:
2026-08-06T06:08:00Z
Author Dr Jonathan Cohen-Gold
2024-01-09T10:09:08
Sponsored by Sartorius iQue®
2026-06-29T06:49:00
Contributor Laura Alvarez, Drug Target Review
2023-01-06T16:37:30
Sponsored by Catalent
2025-04-22T14:58:00
Sponsored by Takara Bio USA
2024-01-19T07:40:55
Sponsored by Euretos
2023-03-08T16:29:20
Sponsored by Bio-Techne
Site powered by Webvision Cloud